{"id":7319,"date":"2015-04-08T17:31:45","date_gmt":"2015-04-08T17:31:45","guid":{"rendered":""},"modified":"2015-04-08T17:31:45","modified_gmt":"2015-04-08T17:31:45","slug":"klinikine-farmakogenomine-studija-nataspin-h-poveikio-isemine-sirdies-liga-sergantiems-ligoniams-tyrimas","status":"publish","type":"post","link":"https:\/\/www.pasveik.lt\/lt\/naujausi-medicinos-straipsniai\/klinikine-farmakogenomine-studija-nataspin-h-poveikio-isemine-sirdies-liga-sergantiems-ligoniams-tyrimas\/7319\/","title":{"rendered":"Klinikin\u0117 farmakogenomin\u0117 studija: NatAspin H poveikio i\u0161emine \u0161irdies liga sergantiems ligoniams tyrimas"},"content":{"rendered":"

\u00a0<\/p>\n

Fiziologin\u0117mis s\u0105lygomis kraujavimas<\/a> sustabdomas vykstant kraujo kre\u0161\u0117jimo procesams. Dalyvaujant trombocitams, i\u0161 fibrinogeno susidaro netirpus fibrino kre\u0161ulys, u\u017ekem\u0161antis pa\u017eeist\u0105 viet\u0105. Normaliai, prasid\u0117jus kraujo kre\u0161\u0117jimo procesams, \u012fsijungia ir fibrinoliz\u0117s sistema. Pagrindinis jos komponentas plazminas ima tirpinti jau susidariusius kraujo kre\u0161ulius (trombus) [1]. I tipo plazminogeno aktyvatoriaus inhibitorius (PAI-1) slopina fibrinoliz\u0117s procesus. Jis slopina plazmino gamyb\u0105 i\u0161 plazminogeno, didina jau susidariusi\u0173 tromb\u0173 stabilum\u0105 ir atsparum\u0105 tirpimui, d\u0117l to trombas u\u017ekem\u0161a kraujagysl\u0119. Retais atvejais d\u0117l genetini\u0173 sutrikim\u0173 nepakankamas b\u016bna ir PAI-1 aktyvumas, d\u0117l to pasirei\u0161kia ilgalaikis kraujavimas<\/a> pa\u017eeidus kraujagysl\u0119 [1]. Dar pra\u0117jusio am\u017eiaus pabaigoje buvo i\u0161siai\u0161kinta, kad d\u0117l PAI-1 aktyvumo kraujyje did\u0117ja rizika sirgti \u0161irdies ir kraujagysli\u0173 ligomis [2]. Didesnis PAI-1 aktyvumas pasteb\u0117tas arterij\u0173 (ma\u017edaug 3 kartus didesnis), bet ne ven\u0173 trombuose [1], o aterosklerozini\u0173 pa\u017eeidim\u0173 vietose, ypa\u010d nutukusiems, sergantiems 2 tipo cukriniu diabetu ligoniams, nustatomas didesnis PAI-1 aktyvumas kraujyje [4, 6]. Keletas PAI-1 geno variant\u0173 (genotip\u0173) gali tur\u0117ti \u012ftakos \u0161io fermento aktyvumui organizme. Da\u017eniausiai tiriamas variantas \u2013 PAI-1 675 4G\/5G. 5G\/5G variant\u0105 turin\u010di\u0173 asmen\u0173 PAI-1 aktyvumas laikomas normaliu. Turintiems 4G\/5G ir 4G\/4G PAI-1 aktyvumas b\u016bna didesnis. \u0160ie asmenys yra labiau link\u0119 sirgti ir cukriniu diabetu, arterine ar venine tromboze, miokardo infarktu su ST segmento pakilimu [11, 12]. PAI-1 aktyvumas gali b\u016bti suma\u017eintas veikiant kai kuriems nat\u016braliems fibrinolizin\u0117s sistemos aktyvikliams. Vienas j\u0173 \u2013 japoni\u0161kame fermentuot\u0173 soj\u0173 pupeli\u0173 produkte natto esantis fermentas natokinaz\u0117 [14]. \u017dinant tai, jog skirting\u0105 PAI-1 genotip\u0105 turin\u010di\u0173 \u017emoni\u0173 PAI-1 aktyvumas skiriasi, \u0161is preparatas tur\u0117t\u0173 skirtingu stiprumu veikti kiekvieno \u017emogaus organizm\u0105. Tod\u0117l m\u016bs\u0173 tyrimo tikslas buvo i\u0161tirti, ar specialios medicinin\u0117s paskirties maisto produktas NatAspin <\/em>turi teigiamos \u012ftakos fibrinoliz\u0117s sistemos aktyvumui ir kaip \u0161is aktyvumas skiriasi nuo genotipo.<\/p>\n

\u00a0\n","protected":false},"excerpt":{"rendered":"

\u00a0 Fiziologin\u0117mis s\u0105lygomis kraujavimas sustabdomas vykstant kraujo kre\u0161\u0117jimo procesams. Dalyvaujant trombocitams, i\u0161 fibrinogeno susidaro netirpus fibrino kre\u0161ulys, u\u017ekem\u0161antis pa\u017eeist\u0105 viet\u0105. Normaliai, prasid\u0117jus kraujo kre\u0161\u0117jimo procesams, \u012fsijungia ir fibrinoliz\u0117s sistema. Pagrindinis jos komponentas plazminas ima tirpinti jau susidariusius kraujo kre\u0161ulius (trombus) [1]. I tipo plazminogeno aktyvatoriaus inhibitorius (PAI-1) slopina fibrinoliz\u0117s procesus. Jis slopina plazmino gamyb\u0105 i\u0161…<\/p>\n","protected":false},"author":1,"featured_media":7320,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[27313],"tags":[],"site":[],"post_item_type":[27345],"class_list":["post-7319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-gydymo-naujienos"],"acf":{"post_sites":false},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/7319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/comments?post=7319"}],"version-history":[{"count":0,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/posts\/7319\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media\/7320"}],"wp:attachment":[{"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/media?parent=7319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/categories?post=7319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/tags?post=7319"},{"taxonomy":"site","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/site?post=7319"},{"taxonomy":"post_item_type","embeddable":true,"href":"https:\/\/www.pasveik.lt\/lt\/wp-json\/wp\/v2\/post_item_type?post=7319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}